Back to search results

A Study of REC-1245 for Advanced Cancers and Lymphomas

This study is testing a new oral medicine called REC-1245 for people with cancers that have spread (metastatic), are locally advanced, or cannot be removed by surgery (unresectable), as well as certain types of lymphoma that have come back or not responded to previous treatments. You might be able to join if your cancer has progressed, come back, or if you can't tolerate or are ineligible for standard treatments. The study aims to see how safe REC-1245 is, how your body handles it, and if it can shrink tumors or stop them from growing. We don't know the current recruitment status for this study.

Study design
This is an open-label study, meaning you and your doctors will know you are receiving REC-1245. The study plans to enroll about 170 participants.
What's involved
Participants will take REC-1245 by mouth once daily for up to two years.
Compensation
Not stated in the trial record.
Follow-up
Your health will be monitored for side effects for 30 days after your last dose of REC-1245, which could be up to approximately 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06678659

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

Recruiting
PHASE1Ages 12+InterventionalTreatment
Recursion Pharmaceuticals Inc.
~170 participants
Updated 2026-08-20 on ClinicalTrials.gov
What's tested:REC-1245

At a glance

Recruiting sites
6 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Phase 1-Part 1A (Dose Finding)- Number of Participants With Dose Limiting Toxicities (DLTs)
Measured over Initiation of study drug through 4 weeks
+2 more outcomes measured

Conditions

Unresectable
Locally Advanced
Metastatic Cancers
Relapsed/Refractory Lymphomas

Explore related trials

LymphomaSolid Neoplasm

NCT06678659

Where you'd take part

This study runs at 7 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • City of Hope

    Duarte, Californiastudy coordinator listed

    Recruiting

  • Cleveland Clinic

    Cleveland, Ohiostudy coordinator listed

    Recruiting

  • McGill University Health Centre (MUHC) - The Montreal

    Québec, Canadastudy coordinator listed

    Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canadastudy coordinator listed

    Recruiting

  • Sarcoma Oncology Research Center

    Santa Monica, Californiastudy coordinator listed

    Recruiting

  • START Mountain Region

    West Valley City, Utahstudy coordinator listed

    Recruiting

  • SCRI Oncology Partners - PPDS

    Nashville, Tennesseeno site contact published

    Withdrawn

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Mihae Song
[email protected]
877-467-3411
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed / refractory lymphoma
Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy.
Eastern cooperative oncology group (ECOG) performance status ≤1; for adolescent participants, Lansky Performance Status Scale or Karnofsky Performance Status Scale score of ≥70.
Measurable disease at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 / Lugano criteria and documented by computed tomography (CT) and / or magnetic resonance imaging (MRI)

Exclusion

Received treatment with another RBM39 degrader
Clinically significant gastrointestinal (GI) or GI malabsorption

What this trial measures

  • Phase 1-Part 1A (Dose Finding)- Number of Participants With Dose Limiting Toxicities (DLTs)Initiation of study drug through 4 weeks

    To characterize the incidence of DLTs

  • Phase 1 and 2 - Number of Participants With a Treatment-emergent Adverse EventInitiation of study drug through 30 days after the last dose (up to approximately 24 months)

    To characterize the incidence of treatment emergent adverse events

  • Phase 2- Objective Response Rate (ORR)Initiation from study drug until disease progression (up to approximately 24 months)

    To assess tumor response